EMT6/AR1.0 was derived from the mouse mammary tumour cell line EMT6/P (Sigma Catalogue number. 96042344) by growth in increasing amounts of doxorubicin over a period of 8 weeks. The cell line showed a 40-fold greater resistance to doxorubicin, which is also known as adriamycin. The line was reported to express a classical multi-drug resistance (MDR) phenotype with hyperexpression of membrane P-glycoprotein and a spectrum of cross-resistance e.g. against vincristine and colchicine. Overexpression of CP22 (sorcin) and mdr 1a gene was reported. Cells were shown to have a reduced intracellular drug accumulation and exhibit a doubling time of 12-15 hours. It is recommended to culture the cells without drug after resuscitation until the first passage.
Split sub-confluent cultures (70-80%) 1:3 to 1:6 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37ºC. Resuscitate in drug-free medium, add doxorubicin after first passage.
其他說明
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.
